Allergan PLC (NYSE:AGN) was downgraded by Vetr from a "strong-buy" rating to a "buy" rating in a research report issued to clients and investors on Tuesday, MarketBeat.com reports. They presently have a $276.34 price target on the stock. Vetr's price objective suggests a potential upside of 10.21% from the company's previous close.
In other Allergan PLC news, Director Nesli Basgoz sold 459 shares of the firm's stock in a transaction that occurred on Wednesday, May 11th. The shares were sold at an average price of $225.10, for a total value of $103,320.90. Following the completion of the transaction, the director now owns 5,242 shares of the company's stock, valued at approximately $1,179,974.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Maria Teresa Hilado purchased 661 shares of the firm's stock in a transaction on Thursday, June 2nd. The stock was acquired at an average cost of $241.57 per share, with a total value of $159,677.77. Following the transaction, the chief financial officer now directly owns 11,957 shares in the company, valued at $2,888,452.49. The disclosure for this purchase can be found here.
AGN has been the topic of several other reports. JPMorgan Chase. reaffirmed an "overweight" rating on shares of Allergan PLC in a research report on Friday, May 13th. Credit Suisse (SIX:CSGN) Credit Suisse Group AG began coverage on shares of Allergan PLC in a research note on Monday, July 25th. They set an "outperform" rating and a $327.00 target price on the stock.
Zacks Investment Research lowered shares of Allergan PLC from a "buy" rating to a "hold" rating in a research note on Tuesday, July 26th. Leerink Swann lowered their target price on shares of Allergan PLC from $340.00 to $272.00 and set an "outperform" rating on the stock in a research note on Wednesday, April 6th.
Finally, Deutsche Bank reissued a "buy" rating on shares of Allergan PLC in a research note on Monday, April 18th. Six equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. The stock presently has an average rating of "Buy" and a consensus price target of $308.30.
Shares of Allergan PLC (NYSE:AGN) traded down 1.61% during midday trading on Tuesday, reaching $250.75. The company had a trading volume of 3,601,333 shares. Allergan PLC has a 52 week low of $195.50 and a 52 week high of $339.00. The firm has a market capitalization of $99.19 billion and a price-to-earnings ratio of 22.44. The stock has a 50-day moving average of $240.30 and a 200 day moving average of $252.64.
Allergan PLC (NYSE:AGN) last announced its quarterly earnings results on Tuesday, May 10th. The company reported $3.04 earnings per share for the quarter, topping the consensus estimate of $3.03 by $0.01. The company had revenue of $3.80 billion for the quarter, compared to analyst estimates of $3.97 billion. The firm's quarterly revenue was up 48.1% on a year-over-year basis. On average, analysts anticipate that Allergan PLC will post $14.17 earnings per share for the current year.
A number of institutional investors have modified their holdings of AGN. Pure Financial Advisors Inc. boosted its position in shares of Allergan PLC by 0.4% in the second quarter. Pure Financial Advisors Inc. now owns 2,596 shares of the company's stock valued at $600,000 after buying an additional 10 shares in the last quarter. YHB Investment Advisors Inc. boosted its position in shares of Allergan PLC by 0.4% in the second quarter. YHB Investment Advisors Inc. now owns 4,899 shares of the company's stock valued at $1,132,000 after buying an additional 18 shares in the last quarter. Kistler Tiffany Companies LLC boosted its position in shares of Allergan PLC by 2.2% in the second quarter. Kistler Tiffany Companies LLC now owns 920 shares of the company's stock valued at $213,000 after buying an additional 20 shares in the last quarter. Miracle Mile Advisors LLC boosted its position in shares of Allergan PLC by 0.4% in the second quarter. Miracle Mile Advisors LLC now owns 4,860 shares of the company's stock valued at $1,200,000 after buying an additional 20 shares in the last quarter. Finally, Twin Capital Management Inc. boosted its position in shares of Allergan PLC by 0.6% in the fourth quarter. Twin Capital Management Inc. now owns 4,379 shares of the company's stock valued at $1,368,000 after buying an additional 26 shares in the last quarter.
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.